Tilray Stock Couldn’t Sustain Its Trump Gains. How Cannabis Earnings Could Help.

When speculation broke out that President Donald Trump could move to reschedule marijuana as a Schedule III drug before the end of 2025, cannabis stocks soared. Those gains were short-lived.